Objective-Endothelial cell activation results in altered cell-cell interactions with adjacent endothelial cells and with infiltrating leukocytes. Eph receptors and their ephrin ligands regulate cell-cell interactions during tissue remodeling, and multiple proinflammatory mediators induce endothelial EphA receptor and ephrinA ligand expression. Therefore, we sought to elucidate the role of EphA receptors and ephrinA ligands in endothelial cell activation and atherosclerosis. Methods and Results-Quantitative reverse transcription-polymerase chain reaction screening for EphA/ephrinA expression in atherosclerosis-prone macrovascular endothelium identified EphA2, EphA4, and ephrinA1 as the dominant isoforms. Endothelial activation with oxidized low-density lipoprotein and proinflammatory cytokines induced EphA2 and ephrinA1 expression and sustained EphA2 activation, whereas EphA4 expression was unaffected. Atherosclerotic plaques from mice and humans showed enhanced EphA2 and ephrinA1 expression colocalizing in the endothelial cell layer. EphA2 activation with recombinant Fc-ephrinA1 induced proinflammatory gene expression (eg vascular cell adhesion molecule-1, E-selectin) and stimulated monocyte adhesion, whereas inhibiting EphA2 (small interfering RNA, pharmacological inhibitors) abrogated both ephrinA1-induced and oxidized low-density lipoproteininduced vascular cell adhesion molecule-1 expression. Conclusion-The current data suggest that enhanced EphA2 signaling during endothelial cell activation perpetuates proinflammatory gene expression. Coupled with EphA2 expression in mouse and human atherosclerotic plaques, these data implicate EphA2 as a novel proinflammatory mediator and potential regulator of atherosclerotic plaque development. (Arterioscler Thromb Vasc Biol. 2012;32:686-695.) Healthcare System, Nashville, TN (J.C.). The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
T he endothelium regulates multiple aspects of atherosclerotic plaque formation and progression. Early during atherogenesis, proinflammatory factors, such as cytokines (tumor necrosis factor-␣ [TNF␣], interleukin-1␤ [IL-1␤]) and oxidized low-density lipoprotein (oxLDL), stimulate endothelial cell activation, resulting in enhanced endothelial permeability, increased cell adhesion molecule expression driving leukocyte recruitment, and dysfunction of the endothelium's antithrombotic properties. 1 Proinflammatory cell adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1, and E-selectin, mediate monocyte extravasation into the atherosclerotic plaque, 2 where they differentiate into macrophages and phagocytose accumulated oxLDL. 3 These activated, lipid-laden macrophages secrete cytokines and mito-genic factors into the vessel wall, perpetuating local inflammation and plaque progression. 1 Clinical manifestations of atherosclerosis most often involve acute thrombosis due to plaque rupture or endothelial denudation (superficial plaque erosion). 4 A smooth muscle cell and extracellular matrix-rich fibrotic cap resists plaque rupture, whereas leukocyte-derived proteases degrade the fibrotic cap and destabilize the plaque. 4 Therefore, endothelial cell activation contributes to plaque initiation, progression, and rupture by promoting local inflammation.
The Eph family of receptor tyrosine kinases, the largest in the mammalian genome, form intercellular interactions with their ephrin ligands that affect cytoskeletal remodeling, cell motility, and cell adhesion/repulsion depending on cell type and Eph/ephrin expression gradients. 5 Mammals express 15 Eph receptors, divided into A-class (EphA1-8 and 10) and B-class (EphB1-6) receptors on the basis of sequence homology and binding preferences for their ephrin ligands (ephrinA1-5, ephrinB1-3). 6 In vascular biology, Ephs and ephrins classically regulate segregation of endothelial cells into veins (EphB4) and arteries (ephrinB2) during development. 7 Additionally, both B-class and A-class Ephs and ephrins mediate angiogenesis in the adult. 8 Recent evidence suggests that B-class ephrins show altered expression in the atherosclerotic plaque and may mediate monocyte targeting to the plaque. 9, 10 However, a causal role for Eph/ephrin signaling in endothelial activation has not been shown.
Although no studies have linked A-class Ephs/ephrins to atherosclerosis, multiple lines of evidence implicate EphA receptors and ephrinA ligands in inflammatory responses. Systemic lipopolysaccharide administration results in increased EphA2 expression in the liver, lungs, and brains of rats, 11 and Myobacterium tuberculosis infection stimulates both ephrinA1 and EphA2 expression in the mouse lung. 12 The ephrinA1 gene was originally identified as a TNF␣inducible immediate-early response gene in human umbilical vein endothelial cells (HUVECs), and TNF␣-induced vascular tube formation requires EphA2-ephrinA1 interactions. 13 EphA receptors and ephrinA ligands on the endothelial cell surface function as counter-receptors that stimulate either lymphocyte adhesion or repulsion in a highly cell typespecific manner. 14, 15 Interestingly, the EphA2 gene resides on a region of chromosome 1 linked to premature myocardial infarction in humans (1p36) 16 and on a region of mouse chromosome 4 linked to enhanced susceptibility to atherosclerosis (Athsq1 locus). 17 Therefore, we sought to characterize the role of EphA/ephrinA interactions in the endothelial cell inflammatory response and their association with atherosclerotic plaque formation.
Methods
EphA/ephrinA expression in human aortic endothelial cells (HAECs), human coronary artery endothelial cells (HCAECs), or HUVECs was determined by quantitative reverse transcriptionpolymerase chain reaction (qRT-PCR) and Western blotting. Endothelial cell activation was induced by treatment with cytokines (TNF␣, IL-1␤), highly oxLDL (CuSO 4 oxidized; relative electrophoretic mobility between 2 and 3 18, 19 ), or recombinant, preconjugated Fc-ephrinA1. Changes in endothelial gene expression after treatment with Fc-ephrinA1 were determined using the StellARray Endothelial Cell Biology qRT-PCR array plate (Lonza). Animal protocols were approved by the Louisiana State University Health Sciences Center-Shreveport institutional animal care and use committee, and all animals were cared for according to the National Institute of Health guidelines for the care and use of laboratory animals. All experiments using human tissue were deemed nonhuman research by the local institutional review board because of exclusive use of postmortem samples. Changes in gene expression in vessels harvested from male apolipoprotein E (ApoE)-null mice fed standard chow or a high-fat Western type diet (Teklad 88137) for either 2 or 6 months was detected by classic immunohistochemistry (diaminobenzidine), immunofluorescence microscopy, and qRT-PCR analysis. Atherosclerotic plaques from human vessels were analyzed by immunohistochemistry. EphA2 activation was assessed by EphA2 immunoprecipitation and Western blotting with a phosphotyrosine-specific antibody (4G10), and EphA2 inhibition was accomplished using 3 different anti-EphA2 small interfering RNA (siRNA) oligos (Sigma-Aldrich, Dharmacon) and a chemical compound (2,5-dimethylpyrrol benzoic acid, Chembridge) that blocks ligand binding to both EphA2 and EphA4.
Results

EphA2 Expression Is Responsive to Atherogenic Mediators
Eph/ephrin signaling differs greatly between cell types, and much of the previous work studying EphA signaling in endothelial cells used microvascular endothelium and HUVECs. Therefore, we first compared EphA/ephrinA expression profiles in macrovascular endothelial cells (HAECs, HCAECs) to that of HUVECs by qRT-PCR ( Figure 1A ). Of the 9 mammalian EphA receptors, only EphA2 and EphA4 receptors showed significant expression. Overall, mRNA derived from HAECs, HCAECs, and HUVECs (isolated from 3 different donors) revealed no difference in EphA receptor expression pattern between macrovascular endothelium and HUVECs.
Local inflammatory stimuli drive endothelial cell activation and atherogenesis 1 and promote EphA2 expression in other systems. 20 ,21 Therefore, we tested whether the proinflammatory atherogenic stimuli TNF␣ (10 ng/mL), IL-1␤ (5 ng/mL), and oxLDL (50 -100 g/mL) affect endothelial EphA2 expression. The cytokines TNF␣ and IL-1␤ stimulated a slow induction of EphA2 mRNA maximal at 1.7-and 1.9-fold at 12 hours posttreatment ( Figure 1B) , followed by EphA2 protein expression maximal at 2.4-and 1.5-fold between 12 and 24 hours posttreatment ( Figure 1C and 1D). In contrast, oxLDL stimulated a transient induction of EphA2 mRNA levels maximal at 2-fold between 6 to 12 hours posttreatment but returning to near baseline levels by 24 hours ( Figure 1B ). However, oxLDL stimulated a sustained increase in EphA2 protein expression to greater than 3-fold at 24 hours posttreatment ( Figure 1C and 1D). These proinflammatory stimuli significantly decreased EphA4 mRNA expression ( Figure IA in the online-only Data Supplement) but did not affect EphA4 protein levels ( Figure IB in the online-only Data Supplement), suggesting that proinflammatory stimuli specifically enhance EphA2 expression but not EphA4.
Because the EphA2 gene resides in a susceptibility locus for premature myocardial infarction in humans (1p36) 16 and atherosclerosis in mice (Athsq1), 17 we next tested whether EphA2 expression correlates with plaque formation in atherosclerosis-prone ApoE-null mice. Eight-to 10-week-old male ApoE-null mice were fed standard chow or a high-fat (21%) Western diet for 8 or 24 weeks to stimulate plaque development. EphA2 expression in the atherosclerotic carotid sinus, innominate artery, aortic arch, and abdominal aorta near the renal artery and femoral artery branch points was determined by immunohistochemistry using an antibody previously verified as EphA2-specific in EphA2 knockout mice. 22 EphA2 displayed minimal expression in atherosclerosis prone vessels of ApoE-null mice fed standard chow ( Figure 1E ) but showed enhanced expression in vessels isolated from mice fed the high-fat Western diet ( Figure 1F and 1G). We observed prominent EphA2 staining in the endothelium overlying both developing fatty streaks ( Figure  1F ) and more advanced atheromas ( Figure 1G ); however, EphA2 remained undetectable in unaffected regions of the same vessels and in nonatherosclerotic vessels. Control tissue incubated with secondary antibody alone showed no staining ( Figure 1H ). Immunofluorescent costaining for endothelial cells (platelet endothelial cell adhesion molecule-1), macrophages (Mac2), and EphA2 demonstrated pronounced EphA2 staining in the endothelial cell layer and moderate EphA2 staining in the cell-cell junctions between adjacent foam cells ( Figure 1I ). Whereas representative plaques from the carotid sinus are shown, similar EphA2 staining patterns in atherosclerotic plaques from other regions ( Figure II in the online-only Data Supplement) implicate EphA2 as a common atherosclerotic plaque component.
To determine whether human atherosclerotic plaques also show enhanced EphA2 expression, we obtained atherosclerosis-prone (carotid sinus, right coronary artery, left anterior descending artery) and resistant (common carotid) arteries excised postmortem during autopsies. H&E-stained sections were examined by a pathologist and scored for plaque grade based on the Stary classification method. 23 Stary scoring of 45 vessels from 25 patients identified a range of plaques from Table I in the online-only Data Supplement) was verified by melt curve analysis and by sequencing of the PCR products. B, qRT-PCR analysis of EphA2 expression in human aortic endothelial cells (HAECs) treated with 10 ng/mL tumor necrosis factor-␣ (TNF␣) (black), 5 ng/mL interleukin-1␤ (IL-1␤) (red), or 50 to 100 g/mL oxidized low-density lipoprotein (oxLDL) (blue) for 0 to 24 hours and lysed simultaneously. Results are normalized to GAPDH and to untreated controls. (nϭ3-7). C and D, EphA2 protein analysis of HAECs treated as in B. nϭ4 -5; *PϽ0.05, **PϽ0.01. E to H, Apolipoprotein E-null mice were fed standard chow (E) or a high-fat Western diet for 2 months (F) or 6 months (G). The carotid sinus was stained for EphA2 (brown) or with no primary antibody (H). nϭ4 mice for each time point. I, Immunofluorescent costaining of an early atherosclerotic plaque with plateletendothelial cell adhesion molecule (PECAM)-1 (endothelium, blue), Mac2 (macrophages, green), and EphA2 (red). Representative ϫ40 images are shown. oxLDL indicates oxidized low-density lipoprotein; ERK, extracellular signal-regulated kinase; TNF, tumor necrosis factor; IL, interleukin. grade 1 to grade 5, with 5 to 14 plaques identified per grade (Tables II and III in the online-only Data Supplement). Nearby sections were stained for EphA2 expression, as well as markers of endothelial cells (von Willebrand factor) and macrophages (CD68). Consistent with murine tissues, the endothelium of nonatherosclerotic vessels lacked EphA2 expression, whereas the endothelium overlying atherosclerotic plaques showed prominent EphA2 expression ( Figure 2 
EphrinA Expression in Models of Atherosclerosis
Previous reports demonstrate that TNF␣ stimulates ephrinA1 expression and EphA2 activation in HUVECs, 13 suggesting that proinflammatory stimuli likely promote EphA2 ligand expression as well. To test this, we next examined ephrinA ligand expression in endothelial cells by qRT-PCR. EphrinA1 expression significantly exceeded ephrinA4 or ephrinA5 expression, whereas ephrinA2 and ephrinA3 exhibited very low to no expression in all 3 endothelial cell types ( Figure  3A ). Like EphA2, cytokine treatment stimulated a rapid and sustained increase in ephrinA1 mRNA ( Figure 3B ), whereas ephrinA4 ( Figure 3C ) and ephrinA5 ( Figure 3D ) mRNA was unaffected. The upregulation in ephrinA1 mRNA coincided with a sustained increase in ephrinA1 protein expression following TNF␣ treatment (1.5-fold from 6 hours to 24 hours) but only a transient induction by IL-1␤ (1.5-2-fold from 1 hour to 6 hours; Figure 3E ). Although oxLDL did not affect ephrinA4 or ephrinA5 mRNA expression ( Figure 3C and 3D), oxLDL significantly reduced ephrinA1 mRNA expression by 24 hours (Figure 3B ) but induced a sustained increase in ephrinA1 protein expression up to 3-fold between 6 and 24 hours posttreatment ( Figure 3E ), suggesting that oxLDL promotes ephrinA1 expression independent of mRNA transcription.
Because these atherogenic mediators stimulate ephrinA1 ligand expression, we assessed subsequent EphA2 activation and tyrosine phosphorylation by immunoblotting EphA2 immunoprecipitates with a phosphotyrosine-specific antibody (4G10). Consistent with the time course for ligand expression, TNF␣ and oxLDL both induced a 1.5-to 2.0-fold Figure 1A . B to D, mRNA expression of ephrinA1 (B), ephrinA4 (C), and ephrinA5 (D) was determined as in Figure 1B. (nϭ3-7) . E, EphrinA1 protein analysis of human aortic endothelial cells (HAECs) treated as in Figure 1B. (nϭ3-4) . Representative immunoblots are shown. F and G, EphA2 phosphorylation (activation) in HAECs treated for 6 or 24 hours with tumor necrosis factor-␣ (TNF␣), interleukin-1␤ (IL-1␤), or oxidized low-density lipoprotein (oxLDL) was determined by EphA2 immunoprecipitation and immunoblotting with an anti-pTyr antibody (4G10). Results were normalized to total immunoprecipitated EphA2 and to untreated controls (NT). nϭ4 to 5; *PϽ0.05, **PϽ0.01. increase in EphA2 phosphorylation by 6 hours that was sustained for at least 24 hours posttreatment ( Figure 3F and  3G) . Surprisingly, IL-1␤ also induced a sustained increase in EphA2 phosphorylation despite only transiently inducing ephrinA1 expression. Addition of medium alone over this same time course did not affect EphA2 receptor phosphorylation ( Figure IVA in the online-only Data Supplement). Although EphA2 transactivation has been described for other receptors, 24 EphA2 transactivation occurs early following receptor activation as opposed to the delayed response to proinflammatory stimuli. As such, none of these proinflammatory stimuli activated EphA2 early following treatment (5-15 minutes) ( Figure IVB in the online-only Data Supplement) but instead induced a significant reduction in EphA2 phosphorylation, suggesting that transactivation of EphA2 is not likely to be a dominant mechanism of EphA2 activation. Taken together, these data demonstrate that multiple atherogenic mediators induce expression of both the EphA2 receptor and its ephrinA1 ligand, resulting in EphA2 activation.
Because ephrinA1 expression in atherosclerotic plaques in vivo may induce endothelial EphA2 activation, we measured EphA2 and ephrinA1 staining in healthy and atherosclerotic vessels harvested from ApoE-null mice. In contrast to EphA2, expression of ephrinA1 was most prominent in the endothelial cell layer overlying the atherosclerotic plaque with minimal staining in the leukocyte infiltrates ( Figure 4A ). To verify colocalization of EphA2 and ephrinA1 in the plaque, individual vessels were costained with antibodies for EphA2 and ephrinA1 and visualized by epifluorescence microscopy. Consistent with conventional immunohistochemistry, EphA2 staining was apparent in both the endothelium and neointima, whereas ephrinA1 staining colocalized with EphA2 in the endothelial layer ( Figure  4B ). EphrinA1 and EphA2 similarly showed enhanced mRNA expression in plaque-prone regions (aortic arch) compared with healthy regions (thoracic aorta) in ApoE-null mice, verifying their concurrent upregulation during atherosclerotic plaque formation ( Figure 4C ).
EphrinA1-Induced Human Aortic Endothelial Cell Gene Expression
To determine how EphA2 signaling affects endothelial cell gene expression, HAECs were stimulated with recombinant ephrinA1 for 3 hours, and changes in mRNA expression were analyzed using a commercial qRT-PCR array for genes involved in endothelial cell physiology (Endothelial Cell Biology array; Lonza StellARray). Changes in gene expression were analyzed by Global Pattern Recognition software (Lonza GPR 2.0) identifying 8 genes significantly regulated in response to ephrinA1 (Table, PϽ0.05). As expected, ephrinA1 enhanced the expression of proangiogenic, prosurvival, and proliferation-associated genes (VEGFR2, 25, 26 COX-2, 27 TYMP 28 ) but decreased expression of antiangiogenic genes (COL18A1 29 ) and lymphangiogenic genes (VEGFR3 30 ). However, ephrinA1 also induced a marked increase in classic atherosclerosis-associated genes 1, 31 involved in inflammatory cell targeting (VCAM-1, 26-fold; E-Selectin, 10-fold) and thrombosis (tissue factor, 9-fold). Interestingly, ephrinA1 also reduced the expression of known atheroprotective genes including collagen XVIII (2.6 fold decrease 32 ) and the calcification inhibitor osteoprotegerin 33 (4-fold decrease), although the latter only reached statistical significance within an 85% confidence interval. Taken together, these data suggest that EphA2 signaling promotes endothelial proinflammatory and prothrombotic gene expression.
To confirm Fc-ephrinA1-induced gene expression, we analyzed ephrinA1-induced VCAM-1 expression at the protein level in various endothelial cell types. As expected, Fc-ephrinA1 induced VCAM-1 expression in HAECs and HCAECs ( Figure 5A ), whereas Fc treatment did not ( Figure  VA in the online-only Data Supplement). However, ephrinA1 failed to induce VCAM-1 expression in HUVECs ( Figure  5A ), potentially explaining why ephrinA1's proinflammatory effect has not been described to date. Fc-ephrinA1 similarly failed to induce VCAM-1, E-selectin, and tissue factor mRNA expression in HUVECs ( Figure VB in the online-only Data Supplement), suggesting that HUVECs lack a critical signaling component linking EphA2 activation to proinflammatory gene expression. To verify that ephrinA1 possesses proinflammatory properties, we performed static monocyte adhesion assays on endothelial cells treated for 5 hours with Fc-ephrinA1. As expected, Fc-ephrinA1 treatment resulted in a Ϸ50% increase in the binding of human monocytic THP-1 cells ( Figure VC in the online-only Data Supplement).
Eph receptor and ephrin ligand interactions are notoriously promiscuous within the A-and B-subfamilies. 34 Because macrovascular endothelial cells also express EphA4 ( Figure  1) , we next tested which EphA receptor (EphA2 or EphA4) mediates ephrinA1-induced VCAM-1 expression. Selectively reducing EphA2 expression by transient transfection with either of 2 separate EphA2 siRNA constructs significantly blunted ephrinA1-induced VCAM-1 expression ( Figure 5B ) with the siRNA efficacy correlating with their degree of EphA2 knockdown (85% and Ͼ90% knockdown; Figure  VIA in the online-only Data Supplement). Whereas siRNA 1 resulted in a greater EphA2 knockdown (85%) than VCAM-1 inhibition (Ϸ50%), this effect may result from a low threshold of EphA2 receptors required to mediate the ephrinA1induced proinflammatory response. Neither EphA2-targeted siRNA affected EphA4 expression ( Figure VIA in the onlineonly Data Supplement), and EphA4-targeted siRNA oligos did not significantly affect VCAM-1 expression ( Figure VIB in the online-only Data Supplement), suggesting that EphA2 is the primary EphA receptor mediating ephrinA1-induced VCAM-1 expression in HAECs.
TNF␣, IL-1␤, and oxLDL all stimulate EphA2 activation, suggesting that EphA2 may facilitate VCAM-1 expression in response to these stimuli. oxLDL-induced VCAM-1 expression was reduced to near-baseline levels after EphA2 knockdown ( Figure 5C ), whereas a chemical competitor for EphA2/ EphA4 ligand binding (2,5-dimethylpyrrol benzoic acid) 35 similarly blocked oxLDL-induced VCAM expression ( Figure  5D ). In contrast, EphA2 depletion did not affect cytokine-induced VCAM-1 expression ( Figure VII 
Discussion
The current work suggests a novel role for endothelial Eph/ephrin signaling in atherosclerotic plaque formation. Atherosclerotic plaques from humans and hypercholesterolemic mice show robust EphA2 expression in the endothelium and in leukocytes, whereas EphA2 expression is undetectable in nonatherosclerotic vessels. Multiple atherogenic mediators induce endothelial EphA2 expression and enhance EphA2 activation concomitant with expression of its ligand eph-rinA1. EphrinA1 colocalizes with EphA2 in the endothelial cell layer of mouse plaques, suggesting that EphA2 expressed within the atherosclerotic plaques likely becomes activated. EphA2 activation with recombinant ephrinA1 stimulates proinflammatory and prothrombotic gene expression as well as enhanced monocyte adhesion, and oxLDL-induced but not cytokine-induced VCAM-1 expression requires EphA2 activation. Taken together, these data suggest that EphA2 activation perpetuates proinflammatory gene expression and atherosclerosis-associated endothelial cell activation.
Following the discovery that EphB4/ephrinB2 demarcated arterial and venous endothelium, 7 only a paucity of studies have characterized EphA/ephrinA signaling in the vasculature. Our current data suggest a novel role for EphA2 as a secondary, chronic effector of inflammatory stimuli as EphA2 shows both sustained expression and activation by atherogenic mediators, as well as the ability to promote inflammatory gene expression. Interestingly, EphA2 is required for oxLDL-induced but not TNF␣-or IL-1␤-induced VCAM-1 expression despite similar levels of EphA2 activation by all 3 treatments. Although the cause of this differential requirement is not immediately obvious, these stimuli differ markedly in the mechanism, amplitude, and duration of VCAM-1 expression. 36, 37 The early, robust proinflammatory response to cytokines stimulates negative feedback pathways, such as IB family member and A20 expression, that limits nuclear factor-B activation and proinflammatory gene expression. 38 Therefore, the self-limiting nature of inflammation may minimize the proinflammatory role of EphA2 activation at the later stages following cytokine treatment but less so following oxLDL treatment. However, from these data we cannot exclude a role for cytokine-induced EphA2 activation in the regulation of endothelial cell phenotype or in the differential expression of proinflammatory genes other than VCAM-1.
Whereas TNF␣, IL-1␤, and oxLDL induced both EphA2 transcription and protein expression, the expression of eph-rinA ligands appears to involve more complex posttranscriptional regulatory mechanisms. IL-1␤ stimulates a sustained increase in ephrinA1 mRNA, with levels remaining over 2-fold baseline by 24 hours; however, protein expression is transient and returns to baseline by 12 hours posttreatment. More strikingly, oxLDL stimulates the greatest induction of ephrinA1 protein expression but does not induce ephrinA1 mRNA transcription. Rather, oxLDL treatment reduces eph-rinA1 mRNA after 24 hours. This disconnect between mRNA levels and protein expression could occur through multiple mechanisms, but perhaps the most intriguing potential mechanism involves regulation by endothelial microRNAs (miRNA). miRNAs can repress protein translation without affecting mRNA levels, 39 suggesting that oxLDL could promote ephrinA1 protein but not mRNA expression by depleting a miRNA construct targeting ephrinA1. Work by Alisi et al found that ephrinA1 protein levels, but not mRNA levels, were negatively correlated with the miR-200b-429 cluster, 40 and this miRNA cluster is downregulated in endothelial cells during hypoxia, consistent with ephrinA1's role in angiogenesis. 41 However, more work will be required to determine whether miRNAs play a role in oxLDL-induced ephrinA1 expression.
Much of the previous work on endothelial cell EphA2 signaling used HUVECs, and the absence of ephrinA1induced inflammation in HUVECs likely explains why our proposed proinflammatory role has gone unnoticed. However, it is unclear why HUVECs do not display ephrinA1induced inflammatory gene expression, because EphA2 is the dominant EphA receptor in these cells and becomes equally activated by ephrinA1. Interestingly, a previous study by Amberger et al demonstrated that oxLDL stimulates VCAM-1 expression in arterial endothelial cells but not in venous endothelial cells, 42 consistent with the role for EphA2 in mediating both ephrinA1-and oxLDL-induced proinflammatory responses in HAECs and HCAECs but not HUVECs. Because EphA2 receptor expression is similar ( Figure 1A) , the lack of a proinflammatory effect in the HUVECs most likely results from the reduced expression of a critical downstream mediator involved in coupling EphA2 activation with proinflammatory gene expression. Future work will use this model system to delineate which signaling pathways are required for EphA2's proinflammatory response.
Monocyte homing to the atherosclerotic plaque critically regulates plaque initiation and is thought to enhance plaque vulnerability through monocyte-dependent degradation of the fibrotic cap. 43 EphA2 and ephrinA1 may affect multiple steps during monocyte homing, including endothelial proinflammatory gene expression, monocyte activation, and transendothelial migration. Our data showed that EphA2/ephrinA1 interactions stimulate the expression of cell adhesion molecules (E-selectin, VCAM-1) that promote monocyte binding, 2 and ephrinA1-activated endothelial cells exhibited enhanced monocyte adhesion. Additionally, EphA2 and ephrinA1 on the luminal endothelial cell surface might interact with counter-receptors on rolling monocytes to regulate monocyte attachment. A similar scenario was recently shown for the classic arterial ephrin, ephrinB2; luminal ephrinB2 on the endothelium interacts with EphB2 on monocytes enhancing monocyte adhesion. 9 T-cell ephrinA ligation by endothelial EphA receptors stimulates T-cell adhesion to endothelial cell surface ligands, whereas endothelial ephrinA ligation of T-cell EphA receptors inhibits adhesion. 15 In contrast to T cells, activation of dendritic cell-expressed EphA2 with ephrinA3 stimulates their adhesion to fibronectin, 14 suggesting that the ability of ephrinA1 and EphA2 to serve as leukocyte counter-receptors may be cell type specific. Furthermore, coexpression of ephrinA1 and EphA2 on atherosclerotic endothelium suggests that the relative balance of ephrinA1 to EphA2 may be an important determinant affecting the availability of these proteins to serve as counter-receptors.
In addition to inflammation, ephrinA1 and EphA2 classically mediate vessel remodeling responses during angiogenesis. 44 In ischemic tissue, angiogenesis plays protective and regenerative roles in clearance and remodeling, and a recent study demonstrated that enhanced ephrinA1 expression on cardiomyocytes leads to activation and recruitment of cardiac stem cells, resulting in increased vessel density and reduced tissue scarring. 45 However, angiogenesis perpetuates inflammation during chronic inflammatory responses by providing additional routes for leukocyte targeting. 46 In the growing atherosclerotic plaque core, hypoxic cells stimulate intraplaque angiogenesis, and angiogenic inhibitors are sufficient to reduce plaque progression. 32 Furthermore, the presence of intraplaque vessels correlates with poor clinical prognosis and enhanced likelihood of plaque instability and hemorrhage. 47 Therefore, limiting EphA2 activity or expression may prevent atherosclerotic plaque formation by reducing both inflammation and intraplaque angiogenesis.
Taken together, our data demonstrate a novel proinflammatory role for EphA2 in macrovascular endothelial cells and implicate EphA2 as a potential proinflammatory mediator of atherosclerotic plaque formation.
